The estimated Net Worth of Noah L. Rosenberg is at least $1.5 Миллион dollars as of 23 September 2020. Noah Rosenberg owns over 750 units of Retrophin stock worth over $1,929 and over the last 11 years he sold RTRX stock worth over $131,947. In addition, he makes $1,369,640 as Chief Medical Officer at Retrophin.
Sign up
Noah Rosenberg RTRX stock SEC Form 4 insiders trading
Noah has made over 6 trades of the Retrophin stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 750 units of RTRX stock worth $13,860 on 23 September 2020.
The largest trade he's ever made was selling 2,500 units of Retrophin stock on 30 July 2019 worth over $49,875. On average, Noah trades about 719 units every 42 days since 2013. As of 23 September 2020 he still owns at least 27,555 units of Retrophin stock.
You can see the complete history of Noah Rosenberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Noah Rosenberg biography
Dr. Noah L. Rosenberg M.D. serves as Chief Medical Officer of the Company. Previously, Dr. Rosenberg served as Chief Medical Officer at Medimetriks Pharmaceuticals, Inc. from May 2014 to June 2018 where he was responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. From February 2012 to May 2014, he served as Chief Medical Officer of Esperion Therapeutics, Inc., where he led the design, protocol implementation, execution and monitoring of innovative clinical programs. Prior to joining Esperion, Dr. Rosenberg served as the Executive Director and Head of cardiovascular and metabolism clinical development for the Forest Research Institute, where he led the advancement of multiple late-stage clinical trials from April 2009 to January 2012. Earlier in his career, he held leadership roles in clinical development, medical affairs and administration at Sanofi Aventis and Pfizer. Dr. Rosenberg completed his internal medicine residency at The Icahn School of Medicine at Mount Sinai Hospital and holds an M.D. from the Drexel University College of Medicine and a B.A. from Johns Hopkins University.
What is the salary of Noah Rosenberg?
As the Chief Medical Officer of Retrophin, the total compensation of Noah Rosenberg at Retrophin is $1,369,640. There are 2 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of $9,679,320.
How old is Noah Rosenberg?
Noah Rosenberg is 53, he's been the Chief Medical Officer of Retrophin since 2018. There are 8 older and 3 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.
What's Noah Rosenberg's mailing address?
Noah's mailing address filed with the SEC is C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, 92130.
Insiders trading at Retrophin
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer и Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
What does Retrophin do?
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
What does Retrophin's logo look like?
Complete history of Noah Rosenberg stock trades at Esperion Therapeutics и Retrophin
Retrophin executives and stock owners
Retrophin executives and other stock owners filed with the SEC include:
-
Eric Dube,
President, Chief Executive Officer, Director -
Elizabeth Reed,
Senior Vice President, General Counsel and Corporate Secretary -
Noah Rosenberg,
Chief Medical Officer -
Peter Heerma,
Chief Commercial Officer -
William Rote,
Senior Vice President and Head of Research and Development -
Laura Clague,
Chief Financial Officer, Senior Vice President -
Stephen Aselage,
Director -
Sandra Poole,
Independent Director -
Gary Lyons,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
Jeffrey Meckler,
Independent Director -
John Orwin,
Independent Director -
Roy Baynes,
Independent Director -
Ron Squarer,
Independent Director -
Suzanne Bruhn,
Independent Director -
Neil F. Mc Farlane,
Chief Operating Officer -
Jensen Margaret E Valeur,
General Counsel -
John W Kozarich,
Director -
Alvin Shih,
EVP of Research & Development -
Cornelius E Golding,
Director -
Steve Aselage,
Director -
Martin Shkreli,
Chief Executive Officer -
Steven Gary Richardson,
Director -
Horacio Plotkin,
Chief Medical Officer -
Jeffrey Paley,
Director -
Marc L Panoff,
Chief Financial Officer